sacituzumab govitecan
gilead sciences
['tropics-02', 'breast']
breast cancer phase 3 tropics-02 results at #asco22: dana-farber's sara tolaney, md, ( ) says research shows new antibody-drug conjugate produced improved progression-free survival rates compared to chemotherapy in hr+/her2-neg advanced #breastcancer
cc: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090